You are here

  • Home
  • Archive
  • Volume 93, Issue Suppl 1
  • J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Article metrics

Article menu
Download PDFPDF
J: Clinical therapeutics
J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

 

Online download statistics by month:

Online download statistics by month: September 2022 to September 2024

AbstractFullPdf
Sep 202219506
Oct 20225903
Nov 20227203
Dec 20225406
Jan 20234002
Feb 20233601
Mar 20235001
Apr 20232401
May 20234201
Jun 20232800
Jul 20231800
Aug 20233401
Sep 2023800
Oct 20231200
Nov 20235402
Dec 20236600
Jan 20241400
Feb 20242000
Mar 20243000
Apr 20241000
May 20243600
Jun 20242200
Jul 20243000
Aug 20242402
Sep 2024500
Total983029